The Tetrahydroisoquinoline Derivative SB269,652 Is an Allosteric Antagonist at Dopamine D3 and D2 Receptors
- 11 August 2010
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Molecular Pharmacology
- Vol. 78 (5), 925-934
- https://doi.org/10.1124/mol.110.065755
Abstract
In view of the therapeutic importance of dopamine D3 and D2 receptors, there remains considerable interest in novel ligands. Herein, we show that the tetrahydroisoquinoline 1H-indole-2-carboxylic acid {4-[2-(cyano-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl]-cyclohexyl}-amide (SB269,652) behaves as an atypical, allosteric antagonist at D3 and D2 receptors. Accordingly, SB269,652 potently (low nanomolar range) abolished specific binding of [3H]nemanopride and [3H]spiperone to Chinese hamster ovary-transfected D3 receptors when radioligands were used at 0.2 and 0.5 nM, respectively. However, even at high concentrations (5 μM), SB269,652 only submaximally inhibited the specific binding of these radioligands when they were employed at 10-fold higher concentrations. By analogy, although SB269,652 potently blocked D3 receptor-mediated activation of Gαi3 and phosphorylation of extracellular-signal-regulated kinase (ERK)1/2, when concentrations of dopamine were increased by 10-fold, from 1 μM to 10 μM, SB269,652 only submaximally inhibited dopamine-induced stimulation of Gαi3. SB269,652 (up to 10 μM) only weakly and partially (by approximately 20–30%) inhibited radioligand binding to D2 receptors. Likewise, SB269,652 only submaximally suppressed D2 receptor-mediated stimulation of Gαi3 and Gαqi5 (detected with the aequorin assay) and phosphorylation of ERK1/2 and Akt. Furthermore, SB269,652 only partially (35%) inhibited the dopamine-induced recruitment of β-arrestin2 to D2 receptors. Finally, Schild analysis using Gαi3 assays, and studies of radioligand association and dissociation kinetics, supported allosteric actions of SB269,652 at D3 and D2 receptors.Keywords
This publication has 44 references indexed in Scilit:
- Allosteric communication between protomers of dopamine class A GPCR dimers modulates activationNature Chemical Biology, 2009
- Effects of (−)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilizationJournal of Neural Transmission, 2008
- S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3versus D2Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled ReceptorsThe Journal of pharmacology and experimental therapeutics, 2007
- Allosteric Interactions with Muscarinic Acetylcholine Receptors: Complex Role of the Conserved Tryptophan M2422Trp in a Critical Cluster of Amino Acids for Baseline Affinity, Subtype Selectivity, and CooperativityMolecular Pharmacology, 2006
- Modulation of Agonist Binding to Human Dopamine Receptor Subtypes by l-Prolyl-l-leucyl-glycinamide and a Peptidomimetic AnalogThe Journal of pharmacology and experimental therapeutics, 2005
- S32504, a Novel Naphtoxazine Agonist at Dopamine D3/D2Receptors: I. Cellular, Electrophysiological, and Neurochemical Profile in Comparison with RopiniroleThe Journal of pharmacology and experimental therapeutics, 2004
- Signaling Mechanisms of the D3Dopamine ReceptorJournal of Receptors and Signal Transduction, 2004
- SB-269652 is a selective D3 receptor antagonist in vitro and in vivoEuropean Neuropsychopharmacology, 1999
- A β-Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor ActivationPublished by Elsevier BV ,1997
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973